ClinicalTrials.gg
CompletedNCT00002450Updated Jun 24, 2005

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

A Phase 3 interventional study of Tenofovir disoproxil fumarate in HIV Infections, sponsored by Gilead Sciences. Completed at 61 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Enrollment
11th of 94
600 · median 99
Phase 3
16 of 98
none open now
Registered
4th of 98
by date
Lead sponsor
17 of 98
Gilead Sciences

Among the 98 studies testing tenofovir in HIV Infections, this one is the 11th largest by enrollment of the 94 interventional ones that give a count, is one of 16 in phase 3, and was the 4th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to see if giving tenofovir DF plus a combination of other anti-HIV drugs is safe and effective.

Read the detailed description

Patients are randomized 2:1 to add tenofovir DF once daily or placebo to their existing antiretroviral regimen in a blinded manner. Patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs taken prior to study entry. Patients and physicians are strongly discouraged from making changes in their antiviral therapies for at least 24 weeks post-randomization. After Week 24, changes in background antiretroviral therapy are permitted. At 24 weeks post-randomization, patients randomized to receive placebo are crossed over to receive open-label tenofovir DF once daily for the remainder of the 48-week study. While on study drug, patients are monitored for safety using periodic physical examinations and serial laboratory tests. Additionally, changes in plasma HIV RNA levels and CD4 cell counts are monitored to assess antiviral efficacy. At the end of the 48-week study period, patients are rolled over into extended dosing until tenofovir DF is commercially available or Gilead Sciences terminates the study.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Drug Administration Schedule
  • RNA, Viral
  • Anti-HIV Agents
  • Viral Load
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are -positive.
  • Have been on stable anti-HIV therapy for at least 8 weeks with no more than 4 anti-HIV drugs at the time of study entry.
  • Have a viral load (level of HIV in the blood) between 400 and 10,000 copies/ml.
  • Have good kidney function.
  • Are 18 to 65 years old.
  • Agree to use a barrier method of (such as condoms) during the study and for 30 days after.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have a new AIDS-related illness diagnosed within 30 days of study entry.
  • Have any other serious medical conditions, including kidney or bone disease, an active infection requiring antibiotics, or cancer (other than Kaposi's sarcoma or certain skin cancers).
  • Have received a vaccine within 30 days of study entry.
  • Are unable to take medications by mouth.
  • Have ever taken tenofovir or adefovir dipivoxil.
  • Have taken certain medications within 30 days of study entry, such as chemotherapy, , medications that affect the kidneys, treatment for Kaposi's sarcoma, or certain experimental drugs.
  • Abuse alcohol or drugs.
  • Are pregnant or breast-feeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
Enrollment
600 participants
06

Study locations

61 sites
  • Univ of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Phoenix Body Positive
    Phoenix, Arizona 85016, United States
  • Ocean View Internal Medicine
    Long Beach, California 90803, United States
  • St Mary's Med Ctr
    Long Beach, California 90813, United States
  • AIDS Healthcare Foundation-Research Center
    Los Angeles, California 90027, United States
  • Kaiser Permanente LAMC
    Los Angeles, California 90027, United States
  • LAC / USC Med Ctr / Infectious Diseases
    Los Angeles, California 90033, United States
  • Cedars Sinai Med Ctr
    Los Angeles, California 90048, United States
  • Tower Infectious Diseases / Med Associates Inc
    Los Angeles, California 90048, United States
  • Robert Scott MD
    Oakland, California 94609, United States
  • UCSD Med Ctr - Owen Clinic
    San Diego, California 921038681, United States
  • Pacific Horizons Med Group
    San Francisco, California 94115, United States
  • Kaiser Foundation Hospital
    San Francisco, California 94118, United States
  • San Francisco VA Med Ctr
    San Francisco, California 94121, United States
  • Harbor UCLA Med Ctr / Research and Educational Institute
    Torrance, California 90502, United States
  • Univ of Colorado / Health Science Ctr
    Denver, Colorado 80262, United States
  • Yale New Haven Hosp / Nathan Smith Clinic
    New Haven, Connecticut 06504, United States
  • Yale-New Haven Hospital
    New Haven, Connecticut 06504, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Physicans Home Service
    Washington, District of Columbia 20037, United States
  • Therafirst Med Ctr
    Fort Lauderdale, Florida 33308, United States
  • ARTCTC
    Fort Pierce, Florida 34950, United States
  • Steinhart Medical Associates
    Miami, Florida 33133, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Hillsborough County Health Dept
    Tampa, Florida 33602, United States
  • Treasure Coast Infectious Disease Consultants
    Vero Beach, Florida 32960, United States
  • AIDS Research Consortium of Atlanta Inc
    Atlanta, Georgia 30308, United States
  • Ponce de Leon Med Ctr
    Atlanta, Georgia 30308, United States
  • Northstar Med Clinic
    Chicago, Illinois 60657, United States
  • Bendel Med Research
    Lafayette, Louisiana 70503, United States
  • Dr Joel Gallant
    Baltimore, Maryland 21205, United States
  • New England Med Ctr
    Boston, Massachusetts 02111, United States
  • Massachusetts Gen Hosp
    Boston, Massachusetts 02114, United States
  • Harper Hosp
    Detroit, Michigan 48201, United States
  • Regions Hosp / HIV/AIDS Program
    St. Paul, Minnesota 55101, United States
  • Univ of NM
    Albuquerque, New Mexico 87131, United States
  • Albany Med College
    Albany, New York 12208, United States
  • Bronx Lebanon Hosp Ctr
    Bronx, New York 10457, United States
  • Brookdale Univ Hosp and Med Ctr
    Brooklyn, New York 112123198, United States
  • Howard Grossman
    New York, New York 10011, United States
  • St Vincent's Hosp
    New York, New York 10011, United States
  • Columbia Univ
    New York, New York 10032, United States
  • Univ of Rochester Medical Center
    Rochester, New York 14642, United States
  • Nalle Clinic / Clinical Research Dept
    Charlotte, North Carolina 28207, United States
  • Ian Baird
    Columbus, Ohio 43214, United States
  • Remington Davis Inc
    Columbus, Ohio 43215, United States
  • Oklahoma Univ Health Science Ctr
    Oklahoma City, Oklahoma 73104, United States
  • Pennsylvania State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Miriam Hosp / Brown Univ
    Providence, Rhode Island 02906, United States
  • Dallas Veterans Administration Med Ctr
    Dallas, Texas 75216, United States
  • Nicholas Bellos
    Dallas, Texas 75246, United States
  • Thomas Street Clinic
    Houston, Texas 77009, United States
  • Univ of Texas / Thomas Street Clinic
    Houston, Texas 77030, United States
  • Univ TX San Antonio Health Science Ctr
    San Antonio, Texas 78284, United States
  • Infectious Diseases Physicians Inc
    Annandale, Virginia 22003, United States
  • Hampton Roads Med Specialists
    Hampton, Virginia 23666, United States
  • Infections Ltd PS
    Puyallup, Washington 98371, United States
  • Infections Ltd / Physicians Med Ctr
    Tacoma, Washington 98405, United States
  • Ponce Univ Hosp
    Ponce, 00731, Puerto Rico
  • Clinical Research Puerto Rico Inc
    San Juan, 009091711, Puerto Rico
  • San Juan AIDS Program
    Santurce, 00908, Puerto Rico
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002450
Lead sponsor
Gilead Sciences
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion